


ISHL

12

**COLOGNE
GERMANY**



**OCTOBER
22-24, 2022**

**FINAL
PROGRAM**



GHSG

Saturday (22.10.2022)

07:30

08:45-10:15 Seminars and Workshops

- Workshop: Living beyond Lymphoma
- Seminar: The HL Microenvironment
- Joint EHA-ISHL Symposium
- Workshop: PET beyond Deauville
- Workshop: Innovation for Older Patients

10:15

Coffee Break

10:30

10:30-12:00 Seminars and Workshops

- Seminar: Radiotherapy: Identifying the Beneficiaries
- Seminar: Learning from Pediatric HL
- Workshop: Bringing Liquid Biopsy to Patients
- Workshop: NLPHL

12:00

Coffee Break

12:15

12:15-13:45 Opening paths to the next chapters of lymphoma treatment by BelGene [P. Borchmann]

- Welcome and Introduction to the topic [P. Borchmann]
- Hodgkin's lymphoma as a model for immuno-oncologic therapeutic approaches to lymphoma [P. Bröckelmann]
- The challenge of the older patient in lymphoma therapy [G. Collins]
- New trends in lymphoma therapy: future role of BTKi / CAR-T / bispecific antibodies [P. L. Zinzani]
- Summary and farewell [P. Borchmann]

13:45

Coffee Break

14:00

14:00-15:30 Early Stages

- [M. André, H.-T. Eich]
- Standard treatment of early-stage HL [J. Radford]
- Individual risk assessment of RT in HL [R. Hoppe]
- Workshop Report: NLPHL [M. S. Binkley, D. Eichenauer, S. Hartmann]
- Oral Abstract Presentations

15:30

Coffee Break

16:00

16:00-17:30 CAR T cell therapy in B Cell NHL: Status quo and future perspectives by BMS [P. Cramer, C. Scheid]

- Status quo of CAR T cell therapy for r/r DLBCL [P. Borchmann]
- New perspective for the treatment of r/r CLL [tbd]
- CAR T - Lessons Learned [C. Scheid]

17:30

Coffee Break

18:00

18:00 Opening Ceremony

- Keynote Lecture: tbd [U. Şahin]

19:00

19:00-20:30 Poster Session

19:00

Welcome Reception

20:30

Scientific Sessions and Main Program

Workshops

Scientific Symposia

Sunday (23.10.2022)

07:30-09:00 Interactive Case Discussion

[Faculty: T. Illidge, J. Zijlstra]

- Presentation of difficult and controversial Hodgkin Lymphoma cases with a focus on interaction and discussion
 - Greyzone Lymphoma [L. Placzés]
 - Anti-PD1 Failure [G. Collins]
 - COVID19 Immunity in lymphoma [S. Mellinghoff]
 - Primary progressive HL [A. S. Jacob]

Coffee Break

09:15-10:15 Emerging Cellular Therapies - a Role in HL?

[S. Ansell, P. Borchmann]

- Cellular Therapy in HL [B. Savoldo]
- Design and optimization of CD30 CARs for cHL [C. Quintarelli]
- Emerging indications for cellular therapy [P. Borchmann]

Coffee Break

10:30-12:00 Living beyond Lymphoma

[M. Björkholm, F. van Leeuwen]

- tbd
- GHSg data on fertility, fatigue and social reintegration and the ongoing EMBrAcE study [K. Behringer]
- WS Report: Living beyond Lymphoma. [F. v. Leeuwen, L. Specht]
- Oral Abstract Presentations

Coffee Break

12:15-13:15 Checkpoint inhibition in HL State of the art and future perspectives by MSD [P. Borchmann]

- Firstline therapy of classical Hodgkin Lymphoma - How can immunotherapy improve outcome? [P. Borchmann]
- The current role of PD-1 inhibition in the treatment of relapsed or refractory classical Hodgkin Lymphoma [B. v. Tresckow]
- Strategies to enhance checkpoint inhibition [P. Bröckelmann]

Coffee Break

14:00-15:30 Older and Frail Patients

- [R. Cordoba, A. Evens]
- Managing an Older Lymphoma Patient [R. Cordoba Mascañano]
- Treatment Strategies in Older HL Patients [A. Evens]
- WS Report: Innovation for Older patients [A. Fossá, P. Bröckelmann]
- Oral Abstract Presentations

Coffee Break

16:00-17:30 Unraveling Complex Treatment Pathways for Patients with Relapsed / Refractory HL by Takeda

- Welcome and Introduction [A. Sureda]
- Navigating Complex Treatment Decisions in R/R HL [T. Vassilakopoulos]
- Challenging Case Study #1 [M. Hutchings]
- Learning from Real-World Evidence to Inform Treatment Decisions in R/R HL [A. Sureda]
- Challenging Case Study #2 [M. Hutchings]

Coffee Break

18:00-19:30 Immunotherapy [P. Armand, P. Zinzani]

- New findings and new challenges since last ISHL [S. Ansell]
- Oral Abstract Presentations
- Vision Corner
 - Stimulus Talks [C. Steidl, P. Bröckelmann, G. Collins]
 - Discussion [Chairs: P. Armand, P. Zinzani, Discussants: C. Steidl, P. Bröckelmann, G. Collins]

Monday (24.10.2022)

07:30-09:00 Advanced Stages [O. Casasnovas, J. Radford]

- Why I recommend...
 - BV-AVD [R. Advani], PET-guided ABVD [A. Fossá], PET-guided eEACOPP [P. Borchmann]
- Discussion forum [Patient: J. Richardson, Nurse: S. Wells, Physician: M. Dreyling]
- WS Report: Learning through International Collaboration [P. Borchmann, A. J. Moskowitz]
- Oral Abstract Presentations

Coffee Break

09:15-10:15 Special Situations in HL

- [R. Hoppe, M. J. Kersten]
- HL in Pregnancy [D. Dierickx]
- HIV-positive HL [O. Balocchi]
- alloSCT in the era of anti-PD1 [A. Sureda]

Coffee Break

10:30-12:00 Genomics, Biology & Microenvironment

- [W. Klapper, R. Küppers]
- Biological Classification of HL by Liquid Biopsy [S. Borchmann]
- Single Cell Transcriptomics of HL [C. Steidl]
- WS Report: Bringing Liquid Biopsy to Patients [S. Borchmann, D. Rossi]
- Oral Abstract Presentations

Coffee Break

12:15-13:45 Bridging the gap between efficacy and toxicity in the treatment of stage IV Hodgkin Lymphoma by Takeda [G. Collins, A. Herrera, P. L. Zinzani]

- Hot Off the Press: The Latest Data for ECHELON-1
- Case Study #1 Female, early-30s
- Case Study #2 Male, late-70s
- Case Study #3 Male, mid-50s
- Q&A

Coffee Break

14:00-15:30 Relapsed / Refractory HL

- [R. Advani, C. H. Moskowitz]
- 1st Relapse of HL [C. H. Moskowitz]
- Novel developments in R / R HL [G. Collins]
- WS Report: PET beyond Deauville, [S. Barrington, M. Hutchings, C. Kobe]
- Oral Abstract Presentations

15:30-16:00 Closing Remarks / Conference Highlights [R. Advani]

16:00-16:30 Farewell



FINAL PROGRAM

Gürzenich Conference Center • Cologne



German Hodgkin Study Group
Chairman: Andreas Engert, MD

IMPRINT

Andreas Engert, MD, Symposium and GHSG Chairman
Sven Borchmann, MD, Symposium Secretary
Paul J. Bröckelmann, MD, Symposium Secretary
Dennis A. Eichenauer, MD, Symposium Secretary

German Hodgkin Study Group
Department I for Internal Medicine
University Hospital of Cologne

ISHL12 is hosted by:
Department I for Internal Medicine
University Hospital of Cologne
Director: Prof. Dr. Michael Hallek

Design: Atelier Henri Winter

Printed by: Linsen Druckcenter GmbH

Photos by courtesy of:
Ralf Juergens, P. 5, 21
Thorsten Kern, P. 12, 13, 27, 30
KölnKongress, P. 14
unsplash.com, P. 15, 16/17, 22/23,

CONFERENCE COMMITTEE

Organizing Committee

Andreas Engert, MD, Symposium and GHSG Chairman
Sven Borchmann, MD, Symposium Secretary
Paul J. Bröckelmann, MD, Symposium Secretary
Dennis A. Eichenauer, MD, Symposium Secretary

German Hodgkin Study Group
Department I for Internal Medicine
University Hospital of Cologne
Kerpener Straße 62, D-50924 Cologne

Phone: +49 (0) 221.478-5933
Fax: +49 (0) 221.478-3778
Email: info@hodgkinsymposium.org
Further Information: www.hodgkinsymposium.org

Conference Management & Industrial Exhibition Secretariat

Gabriele Hanke
Travel & Congress Activities
Marienburger Str. 8; D-40883 Ratingen
Phone: +49 (0) 2102.66936
Fax: +49 (0) 2102.964829
Email: info@tca-hanke.de

INTERNATIONAL SCIENTIFIC COMMITTEE

R. Advani, M. André, S. Ansell, P. Armand, O. Baiocchi, S. Barrington,
C. Baues, M. Björkholm, P. Borchmann, O. Casasnovas, B. Cheson,
G. Collins, J. Connors, V. Diehl, M. Dietlein, H. T. Eich, A. Evens, A. Fosså,
J. Friedberg, S. Hartmann, M. Hertzberg, R. Hoppe, M. Hutchings,
T. Illidge, P. Johnson, W. Klapper, R. Küppers, C. Mauz-Körholz,
A. Moskowitz, C. H. Moskowitz, A. Polltack, J. Radford, J. Raemaekers,
A. Rosenwald, M. Shipp, Y. Song, L. Specht, C. Steidl, A. Sureda,
F. van Leeuwen, W. Wilson, J. Yahalom, J. Zijlstra, P. L. Zinzani

SPONSORS

We thank the following pharmaceutical companies for supporting ISHL:



Takeda Pharmaceuticals U.S.A., Inc. | www.takeda.com



Bristol Myers Squibb | www.bms.com



BeiGene Switzerland GmbH
www.beigene.com/en-eu



Takeda Pharmaceuticals U.S.A., Inc.
www.takeda.com



MSD Sharp & Dohme GmbH
www.msd.de

acromion GmbH
www.acromion-gmbh.com

AstraZeneca GmbH
www.astrazeneca.de

Chugal Pharma Germany GmbH
www.chugaipharma.de

Janssen-Cilag GmbH
www.janssen-cilag.de

Roche Pharma AG
www.roche.de

Tessa Therapeutics Ltd.
www.tessacell.com



ACKNOWLEDGEMENTS

We wish to express our appreciation and gratitude to our partners.

ACADEMIC SPONSORS



Financial support was kindly provided by the Deutsche Forschungsgemeinschaft (DFG) within their program "International Scientific Events".

KARL MUSSHOFF STIFTUNG

The Karl Musshoff Stiftung kindly supports the Karl Musshoff Prize in the categories "Best Clinical Abstract" and "Best Preclinical Abstract" as well as the "Poster Awards".

B. BRAUN-STIFTUNG

DER GESUNDHEIT NEUE WEGE BEREITEN

Financial support was kindly provided by the B. Braun-Stiftung within their program "Scientific Events".

ACADEMIC PARTNERS




EXHIBITION HALL

The scientific exhibition takes place at the Gürzenich Conference Center in the "Isabellensaal" on the first floor.

Opening hours of the Exhibition

Saturday, October 22, 2022	12:00-18:00
Sunday, October 23, 2022	08:00-18:00
Monday, October 24, 2022	08:00-18:00



1. Takeda Pharmaceuticals U.S.A. Inc.
2. BeiGene Switzerland GmbH
3. Janssen-Cilag GmbH
4. Chugai Pharma Germany GmbH
5. Roche Pharma AG
6. MSD SHARP & DOHME GmbH

AstraZeneca 

TABLE OF CONTENTS

Conference and Scientific Committee	3
Sponsors Acknowledgements	4-5
Exhibition	6-7
Table of Contents	9
Welcome	11
General Information	12-15
Scientific Program	
Saturday 22.10.2022	16-21
Workshops Seminars Scientific Program Scientific Symposia	
Opening Ceremony Poster Session	
Sunday 23.10.2022	22-25
Scientific Program Scientific Symposia	
Monday 24.10.2022	26-28
Scientific Program Scientific Symposia Closing Remarks	
Sponsoring	29
Oral and Poster Presentations	
Advanced Stages	31-35
Early Stages	35-36
Genomics, Biology & Microenvironment	36-42
Immunotherapy	42-43
Living beyond Lymphoma	44-47
Older & Frail Patients	47-48
Pediatric HL	48-49
Radiotherapy	49-50
Relapsed/Refractory	51-54
Speakers and Chairs	56-57
Award Winners ISHL12	58-59


WELCOME

Dear Colleagues and Friends,

We warmly welcome you to our 12th International Symposium on Hodgkin Lymphoma (ISHL12), hosted by the German Hodgkin Study Group (GHSg). This Symposium has become the central forum for clinicians and scientists involved in Hodgkin Lymphoma research and therapy, enabling in-depth exchange of the latest results and new ideas. Discussing the relevance of new findings for daily clinical practice in Hodgkin Lymphoma is one of the major goals of this Symposium. It will once more be held at the Gürzenich Conference Center in Cologne, which provides a wonderful communicative environment for discussion and networking.

ISHL12 will cover the most recent results in basic research, diagnostics and treatment of Hodgkin Lymphoma. A major focus will be on older and frail patients as well as early stage patients. A session on emerging cellular therapies will provide an in-depth insight at promising treatment options. Scientific symposia and workshops will complement the program. The Karl Musshoff Prize in the categories "Best Clinical Abstract" and "Best Preclinical Abstract" will be presented during the opening ceremony. On top of that, five Poster Awards have been selected by an international committee, based on the evaluation of their abstracts.

We thank all our contributors and cordially welcome you to ISHL12!



Andreas Engert
Symposium Chairman



Sven Borchmann
Symposium Secretary



Paul J. Bröckelmann
Symposium Secretary



Dennis A. Eichenauer
Symposium Secretary



General Information

Conference Secretariat

Gürzenich Cologne | Martinstraße 29-37 | 50667 Cologne

During the conference, you can contact the Secretariat at

Phone: +49 (0) 173 . 939 0730

Email: info@tca-hanke.de

Opening Hours of the Conference Secretariat

Saturday, October 22, 2022 07:00-18:00

Sunday, October 23, 2022 07:00-19:00

Monday, October 24, 2022 07:00-18:00

Accommodation

For accommodation support, please contact the conference management:

Phone: +49 (0) 2102 . 669 36

Email: info@tca-hanke.de

Name Badge

Please make sure to always wear your badge at the conference. If you lose your badge, we will have to charge you a replacement fee.

Catering

During the breaks, complimentary coffee, fruit and refreshments will be available.



Cloakroom

The cloakroom is located in the basement.

Conference Language

The conference language is English.

Continuing Medical Education

The 12th International Symposium on Hodgkin Lymphoma is certified by the European Board for Accreditation in Hematology (formerly EHA) with 35 EBAH credit points.

Please collect your certificates before departure at the registration desk (in the entrance hall of the Gürzenich).

Insurance

The meeting organizers cannot accept liability for personal injuries sustained to Conference participants or for loss or damage of their personal belongings, neither during nor as a result of the meeting.

Internet

There will be free wifi at the Gürzenich Conference Center. Further details and access codes will be provided on site. You can also use the two on-site internet terminals for web browsing and web-based email access.

Prayer Room

A nondenominational prayer room will be available in the conference center. For further details, please contact the Conference Secretariat.



Registration

Pre-registration will close on *October 21, 2022*. All registrations received on or after *October 22* will be considered as on-site registrations and will be charged the on-site fee.

Full registration will include access to the scientific sessions and exhibition, a copy of the program, the welcome reception on *Saturday (October 22)* and all refreshment breaks. You will also receive a name tag; please wear this name tag at all conference events including the scientific symposia.

No refunds will be given.

Speakers Ready Room

The Speakers Ready Room is located next to the registration desk on the ground floor of the Gürzenich Conference Center. Speakers are requested to hand in their PowerPoint presentations in 16:9 format saved on a stick at least 3 hours before their session or the day before if the session starts early in the morning. We can only accept Windows PowerPoint files for upload to the conference system. It is not permitted to use your own laptops or other devices for uploading the files.

Non-Smoking

Please note that there will be a strict non-smoking policy at all conference facilities.



Transportation

The airports closest to Cologne City are Cologne Bonn Airport (CGN; 15km) and Düsseldorf Airport (DUS; 45km).

From Cologne Bonn Airport you can reach Cologne central station by regional rail in about 30 minutes; from Frankfurt Airport to Cologne it takes only an hour by InterCity Express (ICE) and from Düsseldorf Airport about 45 minutes.

Cologne central station is within walking distance (about 10 minutes) from the Gürzenich Conference Center and the Dorint Hotel. You can also take bus no. 132 and get off at "Gürzenichstraße". The other hotels recommended by the Conference Organization can easily be reached by public transport. Cologne has an efficient public transport system, but the recommended hotels, the venue as well as other places of interest are within a comfortable walking distance from each other. For those who are traveling by car, we recommend to use the parking ground "Heumarkt" (about 3 minutes walking distance from the Gürzenich).

If you want to take a taxi, you can either get in directly at one of the numerous taxi stands or you can order a taxi by phone from one of the taxi call centers (+49 221 170000 or +49 221 2882). Uber and Lyft or other ride sharing services do not operate reliably in Cologne or are not available at all. A taxi will most of the time be the better option.

Welcome Reception

On Saturday evening, the conference will be opened officially. After the Opening Ceremony, all participants are warmly invited to join us at our Get Together event at the Gürzenich Conference Center. This event is a great opportunity to meet and chat with many colleagues involved in Hodgkin Lymphoma research and treatment. Drinks and snacks will be provided.

PROGRAM

Saturday, 22.10.2022



Workshop 1 (parallel sessions)

08:45-10:15

Living beyond Lymphoma **ROOM: GROSSER SAAL**

Flora van Leeuwen (Amsterdam, NL), Lena Specht (Kopenhagen, DK)

08:45-09:15
Patient perspective

Louise Jennings
(Manchester, UK),
Jack Richardson
(Manchester, UK)

09:15-09:35
Organisation of HL survivorship care in the UK,
ADAPT program

John Radford
(Manchester, UK)

09:35-09:55
Organisation of HL survivorship care in the
Netherlands and design of INSIGHT cost-
effectiveness study

Berthe Aleman
(Amsterdam, NL)

09:55-10:15
Organisation of HL survivorship care in the U.S.

Kevin Oeffinger
(Durham, US)



Seminar 1 (parallel sessions)

08:45-10:15

The HL Microenvironment **ROOM: KLEINER SAAL**

Andreas Rosenwald (Würzburg, DE), Margaret Shipp (Boston, US)

08:45-09:15
Lessons from the Periphery - Single Cell Analyses
of the Circulating Immune Signature in Hodgkin
Lymphoma

Margaret Shipp
(Boston, US)

09:15-09:45
Spatial Proteomic Analyses of the Intact Tumor
Microenvironment in Hodgkin Lymphoma - One
Cell or Region at a Time

Scott Rodig
(Boston, US)

09:45-10:15
Microenvironmental Lessons from the NIVAHL Trial

Wolfram Klapper
(Kiel, DE)



Joint EHA-ISHL Symposium **ROOM: RATSSTUBE**

08:45-10:15

Peter Borchmann (Cologne, DE), Martin Dreyling (München, DE)

08:45-09:00
Introduction to GHSG

Peter Borchmann
(Cologne, DE)

09:00-09:15
In memoriam of Ton Hagenbeek

Marie José Kersten
(Amsterdam, NL)

09:15-09:45
Future perspectives for prognostication and MRD
in cHL

Sven Borchmann
(Cologne, DE)

09:45-10:15
EV miRNA in cHL

Michiel Pegtel
(Amsterdam, NL)



Workshop 2 (parallel sessions)

08:45-10:15

PET beyond Deauville **ROOM: WEINKELLER**

Sally Barrington (London, UK), Martin Hutchings (Copenhagen, DK),
Carsten Kobe (Cologne, DE)

08:45-09:15
MTV and Baseline PET biomarkers

Sally Barrington
(London, UK)

09:15-09:45
Latest developments in software and PET
technology

Irene Buvat (Orsay, FR)
shared talk with
Carsten Kobe (Cologne, DE)

09:45-10:15
Imaging response in the context of
immunotherapy

Philippe Armand (Boston, US)
shared talk with
Martin Hutchings
(Copenhagen, DK)

**Workshop 3 (parallel sessions)****08:45-10:15****Innovation for Older Patients** ROOM: MARSILIUSSAAL

Paul Bröckelmann (Cologne, DE), Alexander Fosså (Oslo, NO)

08:45-09:05Lymphoma Biology and Immunosenescence in Older Patients
Alessandra Tucci (Brescia, IT)**09:05-09:25**Efficacy and Safety of Targeted Drugs in Older HL Patients
Ingrid Glimelius (Stockholm, SE)**09:25-09:45**Current and Future Trial Landscape in Older Patients
Alexander Fosså (Oslo, NO)**09:45-10:15**

Open Discussion Forum: Addressing Unmet Needs

**Seminar 2 (parallel sessions)****10:30-12:00****Radiotherapy: Identifying the Beneficiaries** ROOM: GROSSER SAAL

Christian Baues (Cologne, DE), Joachim Yahalom (New York, US)

10:30-11:00Indications and current policy for radiotherapy in early and advanced stage HL based on GHSG randomized studies
Christian Baues (Cologne, DE)**11:00-11:30**Who benefits from adding radiotherapy even if PET-negative based on the RAPID study data
David Cutter (Oxford, UK)**11:30-12:00**The experience of incorporating RT into CAR-T cell salvage programs- Does it apply to HL patients?
Brandon Imber (New York, US)**Seminar 3 (parallel sessions)****10:30-12:00****Learning from Pediatric HL** ROOM: MARSILIUSSAAL

Jonathan W. Friedberg (Rochester, US), Christine Mauz-Körholz (Gießen, DE)

10:30-10:43Framing the discussion and key issues in adolescent and young adult Hodgkin Lymphoma
Christine Mauz-Körholz (Gießen, DE)**10:43-10:56**Brentuximab vedotin (Bv) Demonstrates Superior Event-Free Survival in Pediatric High-Risk Hodgkin Lymphoma
Sharon Castellino (Atlanta, US)**10:56-11:13**SEARCH for CAYAHL initiative
Jamie Flerlage (Memphis, US)**11:13-11:30**Importance of QoL and PROs in long-term follow-up of HL
Susan Parsons (Boston, US)**11:30-11:43**Development and execution of S1826 trial: North American NCTN pediatric / adult collaboration
Jonathan W. Friedberg (Rochester, US)**11:43-12:00**Lessons from European Network for Pediatric Hodgkin Lymphoma
Dieter Korholz (Gießen, DE)**Workshop 4 (parallel sessions)****10:30-12:00****Bringing Liquid Biopsy to Patients** ROOM: KLEINER SAAL

Sven Borchmann (Cologne, DE), Davide Rossi (Bellinzona, CH)

10:30-10:46Liquid Biopsy in Lymphoma: The Swiss Experience
Cristina Piroso (Bellinzona, CH)**10:46-11:02**Liquid Biopsy in Lymphoma: The Cologne experience
Michel Heger (Cologne, DE)**11:02-11:18**Integrating Fragmentomics and MRD in Lymphoma
Leo Meriranta (Helsinki, FL)**11:18-11:26**Challenges in bringing Liquid Biopsy to Lymphoma patients - Kick-off talk for round table
Sven Borchmann (Cologne, DE)**11:26-12:00**Challenges in bringing Liquid Biopsy to Lymphoma patients - Round table
All + Sally Barrington (London, UK), Bastian von Tresckow (Cologne, DE)**Workshop 5 (parallel sessions)****10:30-12:00****NLPHL** ROOM: WEINKELLER

Michael S. Binkley (Stanford, US), Dennis Eichenauer (Cologne, DE), Sylvia Hartmann (Frankfurt, DE)

10:30-11:00Where belongs NLPHL? Biology and pathology
Sylvia Hartmann (Frankfurt, DE)**11:00-11:30**Treatment of NLPHL: what evidence is available?
Dennis Eichenauer (Cologne, DE)**11:30-12:00**The GLOW database: a tool to answer open questions in NLPHL
Michael S. Binkley (Stanford, US)

Scientific Symposium (BeiGene)

12:15-13:45

Opening paths to the next chapters of lymphoma treatment

Peter Borchmann (Cologne, DE) ROOM: GROSSER SAAL

12:15-12:20 Welcome and Introduction to the topic	Peter Borchmann (Cologne, DE)
12:20-12:45 Hodgkin's lymphoma as a model for immuno-oncologic therapeutic approaches to lymphoma	Paul Bröckelmann (Cologne, DE)
12:45-13:10 The challenge of the older patient in lymphoma therapy	Graham Collins (Oxford, UK)
13:10-13:40 New trends in lymphoma therapy: future role of BTKi /CAR-T/bispecific antibodies	Pier Luigi Zinzani (Bologna, IT)
13:40-13:45 Summary and farewell	Peter Borchmann (Cologne, DE)

Scientific Session 1

14:00-15:30

Early Stages ROOM: GROSSER SAAL

Marc André (Yvoir, BE), Hans-T. Eich (Münster, DE)

14:00-14:22 Standard treatment of early-stage HL	John Radford (Manchester, UK)
14:22-14:45 Individual risk assessment of RT in HL	Richard Hoppe (Stanford, US)
14:45-14:51 Workshop Report: NLPHL, Michael S. Binkley (Stanford, US), Dennis Eichenauer (Cologne, DE), Sylvia Hartmann (Frankfurt, DE)	

Q 14:51-15:04 | T020

Interim PET-guided treatment of early-stage nodular lymphocyte-predominant Hodgkin Lymphoma: a subgroup analysis of the GHSG HD16 and HD17 studies
Eichenauer D A, Bühnen I, Fuchs M, Grell R, Moccia A, Zijlstra J M, Hartmann S, Kobe C, Dietlein M, Engert A, Borchmann P

Q 15:04-15:17 | T021

Radiation-Free Therapy as the Initial treatment of Good-prognosis early non-bulky Hodgkin Lymphoma, defined by a low Metabolic Tumor Volume and a negative PET-2 - RAFTING Trial
Gallamini A, Picardi M, Filonenko K, Gotti M, Núñez Céspedes J, Rossi A, Domingo-Domènech E, Giza A, Sorasio R, Trentin L, Bastos Oteiro M, Paszkiewicz-Kozik E, García Sanz R, Patti C, Chauvie S, Bergesio F, Guerra L, Rambaldi A, Sureda Balari A, Zaucha J M

Q 15:17-15:30 | T022

Sharing decisions regarding radiotherapy for Hodgkin Lymphoma: a qualitative study of the experiences of patients and clinicians in the UK
Shakir R, Gilmour-Hamilton C, Bakin C, Gent I, Holloway A, Meeson A, Ramroth J, Ntentas G, Cutter D, Peters M

Scientific Symposium (BMS)

16:00-17:30

CAR T cell therapy in B Cell NHL: status quo and future perspectives ROOM: GROSSER SAAL

Paula Cramer (Cologne, DE), Christoph Scheid (Cologne, DE)

16:00-16:30 Status quo of CAR T cell therapy for r/r DLBCL	Peter Borchmann (Cologne, DE)
16:30-17:00 New perspective for the treatment of r/r CLL	Paula Cramer (Cologne, DE)
17:00-17:30 CAR T - Lessons Learned	Christoph Scheid (Cologne, DE)

OPENING CEREMONY

Gürzenich Conference Center ROOM: GROSSER SAAL

18:00

18:00-18:05 Welcoming Address	Andreas Engert (Cologne, DE)
18:05-18:20 Award Ceremony Karl-Musshoff Awards & Poster Awards. <i>Peter Borchmann, Sven Borchmann, Paul Bröckelmann, Dennis Eichenauer</i>	
18:20-18:30 Introduction to the Keynote Lecturer	Volker Diehl (Cologne, DE)
18:30-19:00 Keynote Lecture	Ugur Şahin (Mainz, DE)



Poster Session with Welcome Reception

19:00

GROUND FLOOR: FOYER AND KLEINER SAAL

Please join the poster presentation and take the chance to discuss the results with your colleagues.



Sunday, 23.10.2022

Scientific Session 2

07:30-09:00

Interactive Case Discussions **ROOM: GROSSER SAAL**

Faculty: Tim Illidge (Manchester, UK), Josee Zijlstra (Amsterdam, NL)

Presentation of difficult and controversial Hodgkin Lymphoma cases with a focus on interaction and discussion

1. Greyzone Lymphoma (*László Pinczés, Debrecen, HU*)
2. Anti-PD1 Failure (*Graham Collins, Oxford, UK*)
3. COVID19 immunity in Lymphoma (*Sybille Mellinghoff, Cologne, DE*)
4. Primary progressive HL (*Anne Sophie Jacob, Cologne, DE*)

Scientific Session 3

09:15-10:15

Emerging Cellular Therapies - a Role in HL?

ROOM: GROSSER SAAL

Steve Ansell (Rochester, US), Peter Borchmann (Cologne, DE)

09:15-09:35

Cellular therapy in HL

Barbara Savoldo
(Chapel Hill, US)

09:35-09:55

Design and optimization of CD30 CARs for cHL

Conchetta Quintarelli
(Rome, IT)

09:55-10:15

Emerging indications for cellular therapy

Peter Borchmann
(Cologne, DE)

Scientific Session 4

10:30-12:00

Living beyond Lymphoma **ROOM: GROSSER SAAL**

Flora van Leeuwen (Amsterdam, NL), John Radford (Manchester, UK)

10:30-10:53

Towards Lung Cancer Screening in Hodgkin Lymphoma Survivors.

Kim Linton (Manchester, UK)

10:53-11:16

GHSG data on fertility, fatigue and social reintegration and the ongoing EMBRACE study

Karolin Behringer
(Cologne, DE)


 11:16-11:21

Workshop Report: Living beyond Lymphoma,
Flora van Leeuwen (Amsterdam, NL), Lena Specht (Kopenhagen, DK)


 11:21-11:34 | T064

Doxorubicin exposure and breast cancer risk in adolescent and adult Hodgkin Lymphoma survivors

Neppelenbroek S I, Geurts Y M, Aleman B M P, Janus C P, Lugtenburg P J, Rademaker S E, De Weijer R J, Schippers M G, Ta B D, Plattel W J, Zijlstra J M, Van Der Maazen R W, Nijziel M R, Ong F, Schimmel E C, Posthuma E F, Kersten M J, Böhmer L H, Muller K, Koene H R, Te Boome L C, Bilgin Y M, De Jongh E, Van Leeuwen F E, Schaapveld M

 11:34-11:47 | T065

Reproduction patterns among Classical Hodgkin Lymphoma Survivors Treated with BEACOPP and ABVD in Sweden, Denmark, and Norway
Entrop J P, Weibull C E, Smedby K E, Jakobsen L H, Øvliisen A K, Molin D, Glimelius I, Marklund A, Holte H, Fosså A, Smeland K B, El-Galaly T C, Eloranta S

 11:47-12:00 | T066

Treatment and sex-specific exposure-based risk-stratification for care of survivors of childhood Hodgkin Lymphoma: A report from the Childhood Cancer Survivor Study

Dinan M, Stratton K, Leisenring W, Yasul Y, Chow E, Tonorezos E, Moskowitz C, Yeh J, Noyd D, Armstrong G, Oeffinger K

Scientific Symposium (MSD)

12:15-13:15

Checkpoint Inhibition in Hodgkin Lymphoma - State of the art and future perspectives

ROOM: GROSSER SAAL

Peter Borchmann (Cologne, DE)

12:15-12:35

FirstLine therapy of classical Hodgkin Lymphoma - How can immunotherapy improve outcome? Peter Borchmann (Cologne, DE)

12:35-12:55

The current role of PD-1 inhibition in the treatment of relapsed or refractory classical Hodgkin Lymphoma Bastian von Tresckow (Cologne, DE)

12:55-13:15

Strategies to enhance checkpoint inhibition Paul Bröckelmann (Cologne, DE)

Scientific Session 5

14:00-15:30

Older and Frail Patients

ROOM: GROSSER SAAL

Raul Cordoba (Madrid, ES), Andrew Evens (New Brunswick, US)

14:00-14:23

Managing an Older Lymphoma Patient Raul Cordoba Mascañano (Madrid, ES)

14:23-14:46

Treatment Strategies in Older HL Patients Andrew Evens (New Brunswick, US)

14:46-14:51

Workshop Report: Innovation for Older patients, *Alexander Fosså (Oslo, NO), Paul Bröckelmann (Cologne, DE)*

Q 14:51-15:04 | T082

AVD - a possible golden standard in the first-line treatment of older classical Hodgkin Lymphoma patients
Øvergaard N, Lia K, Asdahl P, Wikman P, Glimellus I, Lagerlöf I, Johansson A, Hansson L, Enblad G, Linderöth J, Goldkuhl C, Fosså A, Kamper P, Molin D

Q 15:04-15:17 | T083

The Effect of Heart Failure on Management and Outcomes of Older Patients with Hodgkin Lymphoma
Upshaw J, Nelson J, Rodday A M, Kumar A, Klein A, Konstam M, Wong J, Jaffe I, Ky B, Friedberg J W, Mauer M, Kent D, Parsons S K

Q 14:17-15:30 | T084

Treatment patterns and outcomes for Hodgkin's Lymphoma (HL) patients (pts) aged 60 and older: a report from the Brazilian Prospective Hodgkin's Lymphoma Registry
Goveia L, Castro N, De Souza C, Colaço, Villarim C, Traina F, Chiattoni C S, Praxedes M, Solza C, Perobelli L, Baiocchi O, Gaiolla R, Boquimpani C, Braccheri V, Bonamin Sola C, Oliveira De Paula E, Silva R, Ribas A C, Steffenello G, Pagnano K, Soares A, Souza Medina S, Silveira T, Zattar Cecyn K, Carvalho Palma L, De Oliveira Marques M, Spector N, Biasoli I

Scientific Symposium (Takeda)

16:00-17:30

Unraveling Complex Treatment Pathways for Patients with Relapsed / Refractory Hodgkin Lymphoma

ROOM: GROSSER SAAL

16:00-16:05

Welcome and Introduction Anna Sureda (Barcelona, ES)

16:05-16:25

Navigating Complex Treatment Decisions in R/R HL Theodoros Vassilakopoulos (Athens, GR)

16:25-16:40

Challenging Case Study #1 Martin Hutchings (Copenhagen, DK)

16:40-17:00

Learning from Real-World Evidence to Inform Treatment Decisions in R/R HL Anna Sureda (Barcelona, ES)

17:00-17:30

Challenging Case Study #2 Martin Hutchings (Copenhagen, DK)

Scientific Session 6

18:00-19:30

Immunotherapy

ROOM: GROSSER SAAL

Philippe Armand (Boston, US), Pier Luigi Zinzani (Bologna, IT)

18:00-18:20

New findings and new challenges since last ISHL Steve Ansell (Rochester, US)

Q 18:20-18:32 | T057

Circulating tumor DNA in classical Hodgkin Lymphoma patients treated with pembrolizumab and chemotherapy: dynamic response assessment and correlation with baseline total metabolic tumor volume
Lynch R C, Aliq S, Ujjani C S, Poh C, Warren E H, Smith S D, Shadman M, Shustov A, Till B, Raghunathan V M, Tseng Y, Coye H, Shelby M, Ottemiller S, Keo S, Verni K, Du H, Vandermeer J, Gaston A, Rasmussen H, Gulhane A, Chen D L, Martin P, Marzbani E, Voutsinas J, Alizadeh A A, Gopal A K

Q 18:32-18:45 | T058

Safety and Dose-Expansion Study of Combination Favezelimab (anti-LAG-3) Plus Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti-PD-1 Treatment
Timmerman J, Lavie D, Johnson N A, Avigdor A, Borchmann P, Andreadis C, Bazargan A, Gregory G, Keane C, Tzoran I, Vucinic V, Zinzani P L, Zhang H, Pillai P, Nahar A, Herrera A F

18:45-18:53 Vision Corner Stimulus Talk:

The future of translational science in Hodgkin Christian Steidl (Vancouver, CA)

18:53-19:01 Vision Corner Stimulus Talk:

Best use of PD1 blockade in front-line Graham Collins (Oxford, UK)

19:01-19:09 Vision Corner Stimulus Talk:

Leveraging PD1 blockade for cure Paul Bröckelmann (Cologne, DE)

19:09-19:30 Vision Corner: Discussion

Cairs: Philippe Armand, Pier Luigi Zinzani
Discussants: Paul Bröckelmann, Graham Collins, Christian Steidl

Monday, 24.10.2022

Scientific Session 7

07:30-09:00

Advanced Stages **ROOM: GROSSER SAAL**

Olivier Casasnovas (Dijon, FR), John Radford (Manchester, UK)

07:30-07:35 Why I recommend...

BV-AVD Ranjana Advani (Stanford, US)

07:35-07:40 Why I recommend...

PET-guided ABVD Peter Johnson (Southampton, UK)

07:40-07:45 Why I recommend...

PET-guided eBEACOPP Peter Borchmann (Cologne, DE)

07:45-08:30 Discussion forum

Challenging standard recommendations from a patient's, nurse's and physician's perspective

Patient: J. Richardson (Manchester, UK)
Nurse: S. Wells (Manchester, UK)
Physician: M. Dreyling (München, DE)

📅 08:30-08:35

Workshop Report: Learning through International Collaboration, Peter Borchmann (Cologne, DE) Alison J. Moskowitz (New York, US)

Q 08:35-08:47 | T001

FDG-PET and serum TARC levels after one cycle of BV-AVD in advanced stage Hodgkin Lymphoma patients: results from the very early PET-response adapted EORTC-COBRA trial

Diepstra A, Visser L, Fortpied C, Noordzij W, Loft A, Arens A, Sureda-Balari A, Carvalho S, Vranovský A, Sents W, Buhrer E, Platell W J, Hutchings M

Q 08:47-09:00 | T002

Treatment related morbidity in patients with classical Hodgkin Lymphoma: results of the ongoing, randomized phase III HD21 Trial by The German Hodgkin Study Group

Borchmann P, Mocclia A, Greil R, Herzberg M, Fosså A, Hüttmann A, Keil F, Dierlamm J, Schaub V, Hänel M, Novak U, Meissner J, Hellmuth J, Mathas S, Zijlstra J M, Viardot A, Hertenstein B, Martin S, Giri P, Kreissl S, Fuchs M, Schneider G, Rosenwald A, Klapper W, Eich H T, Baues C, Hallek M, Kobe C, Diehl V, Engert A

Scientific Session 8

09:15-10:15

Special Situations in HL **ROOM: GROSSER SAAL**

Richard Hoppe (Stanford, US), Marie José Kersten (Amsterdam, NL)

09:15-09:35

HL in Pregnancy Daan Dierickx (Leuven, BE)

09:35-09:55

HIV-positive HL Otavio Baiocchi (São Paulo, BR)

09:55-10:15

alloSCT in the era of anti-PD1 Anna Sureda (Barcelona, ES)

Scientific Session 9

10:30-12:00

Genomics, Biology & Microenvironment **ROOM: GROSSER SAAL**

Wolfram Klapper (Kiel, DE), Ralf Küppers (Essen, DE)

10:30-10:53

Biological Classification of HL by Liquid Biopsy Sven Borchmann (Cologne, DE)

10:53-11:16

Single Cell Transcriptomics of HL Christian Steidl (Vancouver, CA)

📅 11:16-11:21

Workshop Report: Bringing Liquid Biopsy to Patients, Sven Borchmann (Cologne, DE), Davide Rossi (Bellinzona, CH)

Q 11:21-11:34 | T026

Characterization of cancer-associated fibroblasts in classical Hodgkin Lymphoma

Karihtala K, Leivonen S, Karjalainen-Lindsberg M, Östman A, Pellinen T, Leppä S

Q 11:34-14:27 | T027

High serum levels of Thymus and Activation Related Chemokine (TARC) precede Hodgkin Lymphoma diagnosis by several years

Diepstra A, Nolte I M, Van Den Berg A, Levin L I, Martínez-Maza O

Q 11:47-12:00 | T028

Single-cell RNA sequencing reveals the interplay between circulating CD4 T cells, B cells and cancer-associated monocytes in classic Hodgkin Lymphoma treated with PD-1 blockade. Paczkowska J, Tang M, Wright K T, Song L, Shanmugam V, Luu K, Welsh E L, Cader F Z, Mandato E, Ouyang J, Bai G, Lawton L, Rodig S, Liu X S, Shipp M A

Scientific Symposium

12:15-13:45

(Takeda)

Bridging the gap between efficacy and toxicity in the frontline treatment of stage IV Hodgkin lymphoma

ROOM: GROSSER SAAL

Graham Collins (Oxford, UK), Alex Herrera (Duarate, US), Pier Luigi Zinzani (Bologna, IT)

Hot off the press: The latest data for the frontline treatment of patients with Stage IV CD30+ Hodgkin Lymphoma from ECHELON-1 (details to be confirmed)

Bridging the gap: Balancing efficacy and toxicity in three challenging case studies. A debate and audience discussion with our panel (details to be confirmed)

Audience Q&A (details to be confirmed)

Summary and close (details to be confirmed)

Scientific Session 10

14:00-15:30

Relapsed / Refractory HL ROOM: GROSSER SAAL

Ranjana Advani (Stanford, US), Craig H. Moskowitz (Miami, US)

14:00-14:231st Relapse of HL

Craig H. Moskowitz (Miami, US)

14:23-14:46

Novel developments in R / R HL

Graham Collins (Oxford, UK)

14:46-14:51

Workshop Report: PET beyond Deauville, Sally Barrington (London, UK), Martin Hutchings (Copenhagen, DK), Carsten Kobe (Cologne, DE)

Q 14:51-15:04 | T098

Brentuximab Vedotin plus ESHAP (BRESHAP) versus ESHAP in Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma. Interim Results of the BRESLIBET Prospective Clinical Trial

Sureda-Balari A, Terol M J, Domingo-Domènech E, González Rodríguez A P, Hernández Mohedo F, Núñez Céspedes J, De La Cruz Vicente F, Martínez Muñoz C, Amutio Diaz M E, Córdoba R, Rodríguez Izquierdo A, Romero Domínguez S, Briones Mejide J, Grell R, Moreno Velázquez M, Rubio A, Bastos Oteiro M, Gómez P, Avivi I, Casanova M, Del Campo García R, Noriega V, Sánchez Blanco J J, García Sanz R

Q 15:04-15:17 | T099

High efficacy and durability of second-line therapy with pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin in the phase II study for relapsed and refractory Hodgkin Lymphoma

Moskowitz A J, Shah G, Schöder H, Ganesan N, Hancock H, Davey T, Perez L, Sohail S, Santarosa A, Capadona C, Munayirji B, Kumar A, Lahoud O, Battevi C, Hamlin P, Straus D J, Owens C, Caron P, Intlekofer A, Hamilton A, Horwitz S, Falchi L, Johnson W, Palomba L, Noy A, Matasar M, Pongas G, Salles G, Vardhana S, Sanin B W, Yahalom J, Dogan A, Zelenetz A, Moskowitz C H

Q 15:17-15:30 | T100Long term Follow-up of a Phase I Study Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A trial of the ECOG-ACRIN Research Group (E4412: Arms A-I)
Diefenbach C, Jegede O, Ambinder R, Cohen J, Robertson M, David K, Advani R, Fenske T, Barta S, Palmisiano N, Svoboda J, Morgan D, Karmali R, Kahl B, Ansell S M**Closing Remarks** ROOM: GROSSER SAAL

15:30-16:00

Conference Highlights

Ranjana Advani (Stanford, US)

Farewell

16:00-16:30

We would very much like to thank all of our partners for their generous sponsoring.

Name of Sponsor	Total Sponsoring Amount	Sponsoring Benefit
acromion GmbH	€ 500,00	Flyer distribution
AstraZeneca GmbH	€ 1.000,00	Flyer distribution, Logo
BeiGene Switzerland GmbH	€ 49.600,00	Symposia, Booth
Bristol Myers Squibb	€ 52.000,00	Symposia
Chugai Pharma Deutschland GmbH	€ 2.200,00	Booth
Janssen-Cilag GmbH	€ 4.400,00	Booth
MSD SHARP & DOHME GMBH	€ 39.000,00	Symposia, Booth
Roche Pharma AG	€ 4.400,00	Booth
Takeda Pharmaceuticals U.S.A., Inc.	€ 111.500,00	2 Symposia, Booth, Email Campaign
Tessa Therapeutics Ltd	€ 5.000,00	Coffee Break

ABSTRACTS

ORAL AND POSTER PRESENTATIONS

Posters will be presented during the Poster Session and Welcome Reception (Saturday, October 23, 19:00 to 20:30).

All poster presenters are kindly requested to be presented at their poster boards during that time.

Advanced Stages

Talks

Q T001

FDG-PET and serum TARC levels after one cycle of BV-AVD in advanced stage Hodgkin Lymphoma patients: results from the very early PET-response adapted EORTC-COBRA trial

Diepstra A, Visser L, Fortpied C, Noordzij W, Loft A, Arens A, Sureda-Balari A, Carvalho S, Vranovský A, Sents W, Buhrer E, Plattel W J, Hutchings M

Q T002

Treatment related morbidity in patients with classical Hodgkin Lymphoma: results of the ongoing, randomized phase III HD21 Trial by The German Hodgkin Study Group

Borchmann P, Moccia A, Greil R, Herzberg M, Fosså A, Hüttmann A, Keil F, Dierlamm J, Schaub V, Hänel M, Novak U, Meissner J, Hellmuth J, Mathas S, Zijlstra J M, Viardot A, Hertenstein B, Martin S, Giri P, Kreissl S, Fuchs M, Schneider G, Rosenwald A, Klapper W, Eich H T, Baues C, Hallek M, Kobe C, Diehl V, Engert A

Posters

P003

A retrospective study to evaluate the reliability of staging and risk stratification of adolescent and adult patients with Hodgkin's Lymphoma registered in the Lymphoma clinic at Tata Memorial Centre

Jain H, Singh A, Sengar M, Elpe T, Mehta H, Bagal B, Thorat J, Nayak L, Sharma N

P004

Advanced stage classical Hodgkin Lymphoma (cHL) patients with a positive interim-PET (PET-2) Deauville score (DS) 5 after 2 ABVD cycles: A pooled analysis of individual patient data of three multi-center trials

Viviani S, Pavoni C, Barrington S F, Guerra L, Schöder H, Johnson P, Kirkwood A A, Stephens D M, Friedberg J W, Chauvie S, Knopp M V, Federico M, Enblad G, Corradini P, Gallamini A, Rambaldi A, Tarella C

P005

Age, histotype and stage IV are associated with a shorter survival in patients with Hodgkin Lymphoma, even the PET-adapted era. A single center retrospective study

Visentin A, Cellini A, Cavarretta C A, Romano Gargarella L, Angotzi F, Ruocco V, Zoletto S, Pravato S, Pizzi M, Vianello F, Crimi F, Vio S, Gregianin M, Trentin L

P006

Clinical outcome of classical Hodgkin Lymphoma patients receiving systemic anti-Lymphoma treatment during SARS-COV-2 positivity: Results from the chemo-covid study on behalf of fondazione italiana linfomi

Rusconi C, Puccini B, Visco C, Ricci F, Re A, Zilioli V R, Zerbi C, Hohaus S, Mazzon F, Ciceri M, Guidetti A, Marasco V, Rigacci L

P007

Comparative efficacy of the R-BEACOPP-14 and R-CHOP regimens in the treatment of patients with advanced stages of nodular lymphocyte-predominant Hodgkin Lymphoma (NLPHL) with THRLBCL-like histopathological growth patterns in the tumor biopsy

Dorokhina E, Moiseeva T, Kovrigina A, Shupletsova I, Al-Radi L, Chabaeva Y A, Mangasarova Y

P008

Impact of bone marrow involvement on early PET response and progression-free survival in the HD18 trial for patients with advanced-stage Hodgkin Lymphoma

Voltin C, Kreissl S, Kaul H, Bühnen I, Mettler J, Pabst T, Eichenauer D A, Fuchs M, Diehl V, Dietlein M, Engert A, Borchmann P, Kobe C

P009

Improved Overall Survival with First-Line Brentuximab Vedotin plus Chemotherapy in Patients with Advanced Stage III/IV Classical Hodgkin Lymphoma: An Updated Analysis of ECHELON-1

Hutchings M, Ansell S M, Connors J M, Kim W S, Gallamini A, Ramchandren R, Friedberg J W, Advani R, Evens A M, Smolewski P, Savage K J, Bartlett N L, Eom H, Abramson J S, Dong C, Campana F, Fenton K, Puhlmann M, Straus D J, Radford J

P010

Inferior Outcomes for Young Adults Treated on Advanced Stage Clinical Trials: Report from the HoLISTIC Consortium

Parsons S K, Rodday A M, Friedberg J W, Gallamini A, Hawkes E, Hodgson D, Johnson P, Link B, Maurer M, Nelson J, Savage K J, Upshaw J, Zinzani P L, Evens A M

P011

IPS-7 or IPS-3 to identify very-high risk patients in advanced Classical Hodgkin's Lymphoma: Which score to choose

Almeida C, Costa E, Sousa R, Roque A, Afonso M C, Neves D, Guilherme R, Ruzickova L, Carda J P, Galdes C, Gomes M

P012

Nodular Lymphocyte-predominant Hodgkin Lymphoma a rare disease with good prognosis: a retrospective multicenter experience

Pierdomenico F, Marques R, Neves D, Gaião. Santos J, Saunders C, Pinho Peixeiro R, Henriques M, Tome A, Alves D, Badior M, Lopes T, Leocadio S, Gomes M, Monteiro A, Coutinho R, Pinto A L, Neves A, Fernandes J P, Gomes Da Silva M

P013

Outcomes of first-line treatment (FL) of classical Hodgkin Lymphoma (cHL) in Argentina: a real life multicenter retrospective study

Laura K, Otero V, Mahuad C, Martinez E, Warley F, Garcia Rivello H, Cristaldo N, Kohan D, Garate G, Vicente Reparaz M d l A, Aizpurua M F, Rojas Bilbao E, Cerana S, Funes M E, Plaza I, Foncuberta C, Vijnovich Baron A, Cranco S, Vitriu A, Gomez M, Lavelle J, Casali C, Clavijo M, Melillo L, Cabral Lorenzo M C, Miroli A, Fishman L, Pavlove M, Miodosky M, Cugliari S, Zerga M

P014

Prognostic significance of nutritional indexes (CONUT and PNI) in classical Hodgkin Lymphoma patients

Costa E, Sousa R, Almeida C, Roque A, Afonso M C, Neves D, Guilherme R, Ruzickova L, Carda J P, Geraldes C, Gomes M

P015

Real World Escalated BEACOPDac Delivers Similar Outcomes to Escalated BEACOPP While Potentially Reducing Haematopoietic and Reproductive Toxicity

Santarsieri A, Sturgess K, Brice P, Menne T F, Osborne W, Creasey T, Ardeshta K M, Behan S, Bhuller K, Booth S, Chavda N, Collins G P, Culligan D, Cwynarski K, Davies A, Dutton D, Furtado M, Gallop-Evans E, Hodson A, Hopkins D, Hsu H, Iyengar S, Jones S G, Linton K, Lomas O, Martinez-Calle N, Mathur A, McKay P, Nagumantry S K, O'Mahony D, Phillips B, Phillips N, Rudge J F, Shah N, Stafford G, Sternberg A, Trickey R, Uttenthal B J, Wetherall N, Mcmillan A K, Follows G A

P016

Reduced steroid exposure is safe and does not reduce disease control among Hodgkin Lymphoma patients treated with escalated BEACOPP (eBEACOPP)

Hude Dragičević I, Bašić-Kinda S, Dujmović D, Radman I, Dreta B, Dotlić S, Galunić-Bilić L, Dobrenić M, Kralik M, Rončević P, Aurer I

P017

The role of baseline bulk and dissemination measures as predictors of progression in advanced Hodgkin Lymphoma

Taszner M, Romanowicz G, Knopińska-Postuszny W, Hańska J, Subocz E, Małkowski B, Zaucha J M

P018

Treatment outcomes in classical Hodgkin Lymphoma (HL): 5-year update report from the Brazilian Prospective Registry

Biasoli I, Castro N, Colaço, Villarim C, Traina F, Chiattonne C S, Praxedes M, Solza C, Perobelli L, Baiocchi O, Gaiolla R, Boquimpani C, Buccheri V, Bonamin Sola C, Oliveira De Paula E, Silva R, Ribas A C, Steffenello G, Pagnano K, Soares A, Souza Medina S, Silveira T, Zattar Cecyn K, Goveia L, Carvalho Palma L, De Oliveira Marques M, De Souza C, Spector N

P019

Unfavorable prognostic value of the predominance of THRLBCL-like histopathological growth patterns in nodular lymphocyte-predominant Hodgkin Lymphoma (NLPHL)

Dorokhina E, Moiseeva T, Kovrigina A, Shupletsova I, Al-Radi L, Chabaeva Y A, Mangasarova Y

Early Stages

Talks

Q T020

Interim PET-guided treatment of early-stage nodular lymphocyte-predominant Hodgkin Lymphoma: a subgroup analysis of the GHSG HD16 and HD17 studies

Eichenauer D A, Bühnen I, Fuchs M, Greil R, Moccia A, Zijlstra J M, Hartmann S, Kobe C, Dietlein M, Engert A, Borchmann P

Q T021

Radiation-Free Therapy as the INITIAL treatment of Good-prognosis early non-bulky Hodgkin Lymphoma, defined by a low Metabolic Tumor Volume and a negative PET-2 - RAFTING Trial

Gallamini A, Picardi M, Filonenko K, Gotti M, Núñez Céspedes J, Rossi A, Domingo-Domènech E, Giza A, Sorasio R, Trentin L, Bastos Oteiro M, Paszkiewicz-Kozik E, Garcia Sanz R, Patti C, Chauvie S, Bergesio F, Guerra L, Rambaldi A, Sureda Balari A, Zaucha J M

Q T022

Sharing decisions regarding radiotherapy for Hodgkin Lymphoma: a qualitative study of the experiences of patients and clinicians in the UK

Shakir R, Gilmour-Hamilton C, Bakin C, Gent I, Holloway A, Meeson A, Ramroth J, Ntentas G, Cutter D, Peters M

Posters

P023

PET2-adapted approach after 2 cycles of ABVD is comparable to 2 cycles of BEACOPP escalated and 2 cycles of ABVD and irradiation in early unfavorable Hodgkin Lymphoma

Mocikova H, Markova J, Gaherova L, Maco M, Sýkorová A, Belada D, Lukášová M, Prochazka V, Duras J, Kozak T

P024

Predictive Value of Baseline Metabolic Tumor Volume in Early-Stage Favorable Hodgkin Lymphoma - Data from the Prospective, Multi-center Phase III HD16 Trial

Van Heek L, Stuka C, Kaul H, Müller H, Mettler J, Hitz F, Baues C, Fuchs M, Borchmann P, Engert A, Dietlein M, Voltin C, Kobe C

P025

RADAR: An international phase III, PET response-adapted, randomised trial in progress, comparing ABVD±ISRT with brentuximab vedotin+AVD±ISRT in patients with previously untreated limited-stage classical Hodgkin Lymphoma

Radford J, Adedayo T, Ardavan A, Barrington S F, Berkahn L, Chauvie S, Clifton-Hadley L, Collins G P, Crump M, Cutter D, Edwards D, Hutchings M, Illidge T, Kirkwood A A, Linton K, Moskowitz C H, Patrick P, Phillips B, Shepherd L, Tonino S, Trotman J, Williams J, Wong Doo N

Genomics, Biology & Microenvironment

Talks

Q T026

Characterization of cancer-associated fibroblasts in classical Hodgkin Lymphoma

Karihtala K, Leivonen S, Karjalainen-Lindsberg M, Östman A, Pellinen T, Leppä S

Q T027

High serum levels of Thymus and Activation Related Chemokine (TARC) precede Hodgkin Lymphoma diagnosis by several years
Diepstra A, Nolte I M, Van Den Berg A, Levin L I, Martínez-Maza O

Q T028

Single-cell RNA sequencing reveals the interplay between circulating CD4 T cells, B cells and cancer-associated monocytes in classic Hodgkin Lymphoma treated with PD-1 blockade

Paczkowska J, Tang M, Wright K T, Song L, Shanmugam V, Luu K, Welsh E L, Cader F Z, Mandato E, Ouyang J, Bai G, Lawton L, Rodig S, Liu X S, Shipp M A

Posters

P029

Are Reed-Sternberg cells stuck in mitosis by short nucleoplasmic bridges as a consequence of centromeric instability?

M'Kacher R, Junker S, Colicchio B, Najjar W, Mika J, Dieterlen A, Polanska J, Voisin P, Jeandidier E, Carde P

P030

Baseline IgM amount can identify patients with adverse outcome despite a PET-2 adapted treatment in classical Hodgkin Lymphoma: results from a real-life single-center study i

Romano A, Cerchione C, Santuccio G, Le Moli M, Chiarenza A, Figuera A, Motta G, Caruso L, Lanza S, Petronaci A, Poidomani S, Ippolito M, Di Raimondo F

P031

CD4+ T cells in close proximity to Hodgkin-Reed Sternberg cells are antigen experienced, polyclonal and display an exhausted phenotype

Veldman J, Rodrigues Praça, J, Chong L, Terpstra M, Mastik M, Van Kempen L C, Aoki T, Steidl C, Van Den Berg A, Visser L, Diepstra A

P032

Circulating immune biomarkers in classical Hodgkin Lymphoma in relation to tumor burden and response to treatment

Mulder T A, Andersson M L, Peña-Pérez L, Heimersson K, Xagoraris I, Wahlin B E, Månsson R, Hansson L, Rassidakis G Z, Palma M

P033

Clinical significance of the severity of THRLBCL-like areas in nodular lymphocyte predominant Hodgkin Lymphoma

Shupletsova I, Kovrigina A, Dorokhina E, Moiseeva T

P034

Correlation between MTV, TLG and Serum TARC Concentration in Classical Hodgkin Lymphoma during First-Line Treatment

Romano I, Puccini B, Abenavoli E, Signori L, Palazzo M, Ciceri M, Sordi B, Berti V, Zizza M, Pancani F, Nassi L, Vannucchi A M

P035

CRISPR/Cas9-mediated knockout reveals an important role of CD30 in Hodgkin and Reed-Sternberg cells of classical Hodgkin Lymphoma

Killian A L, Lollies A, Weniger M A, Küppers R

P036

Detection of recurrent somatic variants in cell-free DNA as a tool for disease monitoring in Hodgkin Lymphoma

Grohmann J, Kredatusova A, Navratilova J, Hanackova V, Urbankova H, Prochazka V, Papajik T

P037

High breadth whole exome sequencing of circulating tumor DNA identifies novel recurrent genetic alterations in Hodgkin Lymphoma

Mammadova L, Heger J, Mattlener J, Sobesky S, Cirillo M, Bröckelmann P J, Altmüller J, Kirst E, Kreissl S, Lohmann M, Nürnberg P, Engert A, Borchmann P, Von Tresckow B, Borchmann S

P038

HLA expression patterns of Hodgkin-Reed-Sternberg cells shape a spatially arranged tumor microenvironment in classical Hodgkin Lymphoma

Müller-Meinhard B, Reinke S, Seifert N, Engert A, Bröckelmann P J, Altenbuchinger M, Klapper W

P039

HLA expression status and prognostic impact of B-cell content in patients with early-stage unfavorable Hodgkin Lymphoma

Grund J, Reinke S, Plütschow A, Von Tresckow B, Borchmann P, Engert A, Bröckelmann P J, Klapper W

P040

LINE-1 reverse transcriptase activity in Hodgkin Lymphoma cells

Wadel A, Jaster L, Staeger M S

P041

Low percentage of T lymphocytes in Hodgkin's Lymphoma lymph nodes, measured by flow cytometry, is associated with inferior progression free survival regardless of negative interim pet scan status

Korin L, Cranco S, Fuente L, Vitriu A, Ochoa P, Babuin E, Gelo O, Ayala L, Novoa A, Tempra P, Venegas M B, Vijnovich Baron A, Tartas N, Custidiano R, Foncuberta C, Sanchez Avalos J

P042

Metabolic regulation of adaptive response to arginine deprivation in Hodgkin Lymphoma

Romano A, Scandura G, Santuccio G, Puglisi F, Cambria D, Amorini A M, La Spina E, Parrinello N L, Giallongo C, Tibullo D, Cerchione C, Martinelli G, Simonetti G, Di Raimondo F

P043

Molecular pathogenesis of Hodgkin Lymphoma

Beeck L, Schneider M, Farsijani N, Budeus B, Bein J, Schaefer H, Hartmann S, Hansmann M, Küppers R

P044

PIM kinases support protumoral and immunosuppressive phenotype and functions of macrophages in classical Hodgkin Lymphoma
Szydłowski M, Garbicz F, Kurtz E, Pawlak M, Górniak P, Szumera-Ciećkiewicz A, Sokół K, Kawecka M, Owczarek D, Puton B, Prochorec-Sobieszek M, Bellarosa D, Kurlapski M, Zaucha J M, Juszczynski P

P045

Plasma proteome profiling of cardiotoxicity in patients with Hodgkin Lymphoma
Mattsson Ulfstedt J, Freyhult E, Christersson C, Mörth C, Kamali-Moghaddam M, Eriksson A, Enblad G, Molin D

P046

Preclinical evaluation of novel repurposed drug combinations in Hodgkin Lymphoma
Lohmann M, Buchberger I, Beielstein A, Kaçar B, Mattlener J, Nill M, Shi Z, Heger J, Pallasch C, Ullrich R, Borchmann S

P047

Predictive role of the Hodgkin Lymphoma-associated cytokines: a prospective study of the Czech Hodgkin Study Group
Prochazka V, Mociškova H, Sykorova A, Markova J, Lukášová M, Gaheřova L, Kredatusova A, Kriegova E, Maco M, Kozak T, Belada D, Papajik T

P048

Predictors of risk of relapse in classic Hodgkin Lymphoma by flow cytometry
Fromm J, Tang C, Naresh K N

P049

Reduced features of T-cell activation before and during anti-PD-1 treatment in classical Hodgkin Lymphoma
Seifert N, Reinke S, Grund J, Müller-Meinhard B, Engert A, Bröckelmann P J, Klapper W, Altenbuchinger M

P050

Reed-Sternberg cells accelerate glycolytic and mitochondrial metabolism of tumor microenvironment cells
Kurlapski M, Szydłowski M, Braczkowski A, Frańczak M, Zieliński M, Smoleński R, Juszczynski P, Zaucha J M

P051

Serum procalcitonin levels in newly diagnosed classical Hodgkin Lymphoma (cHL): Correlation with other inflammatory biomarkers
Piperidou A, Zografos E, Vassilakopoulos T P, Angelopoulou M K, Hlias G, Pappis V, Boutsikas G, Dimou M, Petevi K, Kanellopoulos A, Kyrtonis M, Panayiotidis P, Vassilakopoulos T P

P052

Targeting CSN5/JAB1 oncogene in classical Hodgkin Lymphoma (cHL)
Xagoraris I, Stathopoulou K, Renken S, Lundqvist A, Claret F X, Drakos E, Rassidakis G Z

P053

The cGAS-STING anti-tumor immune response pathway as a potential therapeutic target in classical Hodgkin Lymphoma (cHL)
Xagoraris I, Stathopoulou K, Xyderou P, Palma M, Drakos E, Vassilakopoulos T P, Rassidakis G Z

P054

The Kinase CK2 is deregulated and targetable in classical Hodgkin Lymphoma
Visentini A, Ruggeri E, Frezzato F, Pizzi M, Cellini A, Angotzi F, Cavarretta C A, Ruocco V, Pravato S, Severin F, Facco M, Manni S, Piazza F, Trentin L

P055

Validation of the tumor cell-specific rearranged IgG-encoding circulating cell-free DNA for the treatment response monitoring in patients with classic Hodgkin Lymphoma
Buhtoiarov I, Hill B, Kirsch I, Richter N, Hanna R

P056

Variants of the transcription factor ONECUT2 regulate gene expression in Hodgkin Lymphoma cells

Lein P, Anchang C G, Volkmer I, Staeger M S

P115

Distinct signaling pathways and checkpoint molecule expression across histological subtypes of nodular lymphocyte-predominant Hodgkin lymphoma

Kalashnikov I, Kositsky R, Karjalainen-Lindsberg M, Dunkel J, Pasanen A, Love C, Parker C, Ondrejka S, Hsi E, Juskevicius R, Evans A, Evans A G, Czader M, Wang L, Xu M, Paulson N, Ølgod Pedersen M, Ortved Gang A, Koff J, McCall C, Natkunam Y, Louissaint A, Yeu O S, Pillai R, Chapman J, Amador C, Chadburn A, Goswami R, Behdad A, Sojltra P, Tse E, Kikkeri N, Nasresh K N, Fedoriw Y, Dave S, Leppä S

Immunotherapy

Talks

Q T057

Circulating tumor DNA in classical Hodgkin Lymphoma patients treated with pembrolizumab and chemotherapy: dynamic response assessment and correlation with baseline total metabolic tumor volume

Lynch R C, Alig S, Ujjani C S, Poh C, Warren E H, Smith S D, Shadman M, Shustov A, Till B, Raghunathan V M, Tseng Y, Coye H, Shelby M, Ottemiller S, Keo S, Verni K, Du H, Vandermeer J, Gaston A, Rasmussen H, Gulhane A, Chen D L, Martin P, Marzbani E, Voutsinas J, Alizadeh A A, Gopal A K

Q T058

Safety and Dose-Expansion Study of Combination Favezelimab (anti-LAG-3) Plus Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti-PD-1 Treatment

Timmerman J, Lavie D, Johnson N A, Avigdor A, Borchmann P, Andreadis C, Bazargan A, Gregory G, Keane C, Tzoran I, Vucinic V, Zinzani P L, Zhang H, Pillai P, Nahar A, Herrera A F

Posters

P059

Multi-effector cell targeting with half-life extended bispecific scFv in Hodgkin Lymphoma

Shi Z, Kern V, Frelhammer M, Schitz J, Borchmann S

P060

Prognosis of patients with relapsed and refractory classic Hodgkin Lymphoma after nivolumab discontinuation and efficacy of nivolumab retreatment

Fedorova L, Lepik K, Mikhailova N, Kondakova E, Komarova Y, Kotselyabina P, Borzenkova E, Baykov V, Moiseev I, Kulagin A

P061

Safety and Dose-Expansion Study of Combination Favezelimab (anti-LAG-3) Plus Pembrolizumab in Anti-PD-1-Naive Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Borchmann P, Johnson N A, Lavie D, Gregory G, Herrera A F, Minuk L, Vucinic V, Armand P, Avigdor A, Gasiorowski R, Herishanu Y, Keane C, Kuruvilla J, Palcza J, Pillai P, Nahar A, Timmerman J

P062

The efficacy and safety of nivolumab 40mg therapy versus 3mg/kg in patients with relapsed and refractory classic Hodgkin Lymphoma

Fedorova L, Lepik K, Mikhailova N, Kondakova E, Komarova Y, Kotselyabina P, Borzenkova E, Baykov V, Moiseev I, Kulagin A

P063

Trial in Progress: Individualized Immunotherapy in Early-Stage Unfavorable Hodgkin Lymphoma - The Investigator-Initiated Phase II GHSG INDIE Trial

Bröckelmann P J, Kaul H, Fuchs M, Kobe C, Baues C, Borchmann P, Engert A

Living beyond Lymphoma

Talks

Q T064

Doxorubicin exposure and breast cancer risk in adolescent and adult Hodgkin Lymphoma survivors

Neppelenbroek S I, Geurts Y M, Aleman B M P, Janus C P, Lugtenburg P J, Rademaker S E, De Weijer R J, Schippers M G, Ta B D, Plattel W J, Zijlstra J M, Van Der Maazen R W, Nijziel M R, Ong F, Schimmel E C, Posthuma E F, Kersten M J, Böhmer L H, Muller K, Koene H R, Te Boome L C, Bilgin Y M, De Jongh E, Van Leeuwen F E, Schaapveld M

Q T065

Reproduction patterns among Classical Hodgkin Lymphoma Survivors Treated with BEACOPP and ABVD in Sweden, Denmark, and Norway

Entrop J P, Weibull C E, Smedby K E, Jakobsen L H, Øvlisen A K, Molin D, Glimelius I, Marklund A, Holte H, Fosså A, Smeland K B, El-Galaly T C, Eloranta S

Q T066

Treatment and sex-specific exposure-based risk-stratification for care of survivors of childhood Hodgkin Lymphoma: A report from the Childhood Cancer Survivor Study

Dinan M, Stratton K, Leisenring W, Yasui Y, Chow E, Tonorezos E, Moskowitz C, Yeh J, Noyd D, Armstrong G, Oeffinger K

Posters

P067

A pilot of lung cancer screening for survivors of Hodgkin Lymphoma

Broadbent R, Crosbie P, Radford J, Armitage C J, Taylor B, Mercer J, Tenant S, Linton K

P068

A Retrospective Analysis of Fertility in Female Patients with Advanced Stages of Hodgkin Lymphoma Treated with BEACOPP Escalated Chemotherapy (25 Year Experience of a Single Centre)

Marková J, Mocíková H, Gaherová L, Klásková K, Maco M, Dedeckova K, Kozak T

P069

Characterisation of influencing parameters on oocyte quality preservation in a cohort of Hodgkin Lymphoma patients

Chuzel C, Simon V, Béhal H, Morschhauser F, Decanter C, Nudel M

P070

Design of the INSIGHT study, evaluation of long-term follow-up care for Lymphoma survivors in the Netherlands: does survivorship care at the BETER clinics reduce morbidity and mortality from late effects of Lymphoma treatment and associated costs?

Nijdam A, Lammers E M, Aleman B M P, Zijlstra J M, Van Leeuwen F E

P071

First results of cardiovascular screening in a survivorship care program for Hodgkin Lymphoma survivors in the Netherlands

Lammers E M, Nijdam A, Zijlstra J M, Janus C P, De Weijer R J, Van Leeuwen F E, Aleman B M P

P072

Impact of Ageing on the Survivorship Experiences of Patients with Hodgkin Lymphoma

Bates C, Bamigbola F, Warwick L

P073

Increased risk of colorectal cancer following treatment for Hodgkin Lymphoma

Geurts Y M, Shakir R, Ntentas G, Roberti S, Aznar M, John K, Ramroth J, Janus C P, Krol A, Roesink J, Van Der Maazen R W, Zijlstra J M, Darby S, Aleman B M P, Van Leeuwen F E, Cutter D, Schaapveld M

P074

Long-Term Cause-Specific Mortality in Hodgkin Lymphoma Patients - A Nationwide Danish Cohort Study

Rossetti S, Jacobsen Juul S, Eriksson F, Warming P E, Glíngé C, El-Galaly T C, Haaber Christensen J, Kamper P, De Nully Brown P, Vestmø Maraldo M, Tfelt-Hansen J, Hutchings M

P075

My Hodgkin, My Health: Feasibility of a mobile application to collect long term follow up data about Hodgkin patients

Kailainathan G, Falconer J, Baker A, Wong Doo N, Trotman J

P076

Pneumococcal infection in splenectomised Hodgkin Lymphoma patients: Do they pose a problem today and what is the best long-term strategy?

Björkholm M, Weibull C E, Dickman P

P077

Predicting radiotherapy dose to the heart and the risk of radiation-related cardiac toxicity for Hodgkin Lymphoma patients, using pre-chemotherapy PET-CT scans

Shakir R, Butterworth V, Ntentas G, Ramroth J, Cutter D

P078

Predicting the Health-Related Quality of Life of Hodgkin Lymphoma Survivors: Identification of Risk Factors

Stadtbaeumer N, Mayer A, Borchmann P

P079

PROCTCAE as a patient-reported outcome measurement (PROM) questionnaire in patients with Hodgkin Lymphoma captures different adverse events profile than those reported by physicians

Ramos-Cillan S, Castillo E, Riesco M, Herrero A, Pascual A, Lopez-Garcia A, Perez M A, Morillo D, Askari A, Prieto E, Llamas P, Becares J, Barriocanal C, Del Olmo M, Short J, Arcos J, Córdoba R

P080

The BETER-REFLECT Biobank: a REsource For studies on Late Effects of Cancer Treatment

Mieras A, Nijdam A, Aleman B M P, Daniels L, De Jongh E, Janus C P, Krol S, Ta B D, Ong F, Van Spronsen D J, Posthuma W, Plattel W J, Oostvogels R, Verschueren K, Zijlstra J M, Van Leeuwen F E

P081

Treatment-related circulatory diseases and mortality in Hodgkin Lymphoma patients using multi-state modelling and relative survival

Baech J, Jakobsen L H, El-Galaly T C, Molin D, Glimelius I, Entrop J P, Crowther M J, Smedby K E, Eloranta S, Weibull C E

Older & Frail Patients

Talks

Q T082

AVD - a possible golden standard in the first-line treatment of older classical Hodgkin Lymphoma patients

Övergaard N, Lia K, Asdahl P, Wikman P, Glimelius I, Lagerlöf I, Johansson A, Hansson L, Enblad G, Linderöth J, Goldkuhl C, Fosså A, Kamper P, Molin D

Q T083

The Effect of Heart Failure on Management and Outcomes of Older Patients with Hodgkin Lymphoma

Upshaw J, Nelson J, Rodday A M, Kumar A, Klein A, Konstam M, Wong J, Jaffe I, Ky B, Friedberg J W, Mauer M, Kent D, Parsons S K

Q T084

Treatment patterns and outcomes for Hodgkin's Lymphoma (HL) patients (pts) aged 60 and older: a report from the Brazilian Prospective Hodgkin's Lymphoma Registry
Govela L, Castro N, De Souza C, Colaço. Villarim C, Traina F, Chiattonne C S, Praxedes M, Solza C, Perobelli L, Baiocchi O, Gaiolla R, Boquimpani C, Buccheri V, Bonamin Sola C, Oliveira De Paula E, Silva R, Ribas A C, Steffenello G, Pagnano K, Soares A, Souza Medina S, Silveira T, Zattar Cecyn K, Carvalho Palma L, De Oliveira Marques M, Spector N, Biasoli I

Poster

P085

Epidemiology and results of the first line therapy of HIV-related Hodgkin Lymphoma: Russian retrospective multicenter study
Chekalov A, Popova M, Tsygankov I, Rogacheva Y, Volkov N, Beynarovich A, Lepik K, Demchenkova M, Grigorieva M, Schneider T, Kopeikina Y, Medvedeva N, Zyuzgin I, Pavlyuchenko E, Levanov A, Myasnikov A, Mikhailova N, Baykov V, Kulagin A

Pediatric HL

Talk

Q T087

Brentuximab vedotin (Bv) Demonstrates Superior Event-Free Survival in Pediatric High-Risk Hodgkin Lymphoma
Castellino S M, Pei Q, Parsons S K, Hodgson D, Mccarten K, Horton T, Cho S, Wu Y, Punnett A, Dave H, Henderson T O, Hoppe B S, Charpentier A, Keller F G, Kelly K M

Posters

P086

Advancing Pediatric Hodgkin Lymphoma Research Through NODAL
Flerlage J E, Birz S, Castellino S M, Appel B, Furner B, Graglia L, Henderson T O, Hodgson D, Hoppe B S, Kahn J, Keller F G, Kessel S, Li C, Li M, Lucas J, Mccarten K, Metzger M, Milgrom S, Parsons S K, Pei Q, Wu Y, Zhou Y, Watkins M, Volchenbaum S, Kelly K M

P088

Case series of Nodular Lymphocyte Predominant Hodgkin Lymphoma from Tanzania. A common entity in East Africa?
Kahakwa A, Mkwizu E, Mremi A, Mapendo P, Henke O

P089

Pembrolizumab in Pediatric and Young Adults Patients With Newly Diagnosed Classical Hodgkin Lymphoma and Slow Early Responders to Frontline Chemotherapy: The Phase 2 KEYNOTE-667 Study
Vinti L, Daw S, Sabado Alvarez C, Fagioli F, Beishuizen A, Michel G, Moleti M L, Cepelova M, Thorwarth A, Rigaud C, Plaza Lopez De Sabando D, Landman Parker J, Zhu Y, Pillai P, Nahar A, Mauz-Koerholz C

P090

Staging of Lung Lesions Survey Demonstrates Continued Need for Harmonization
Seelisch J, Kaste S C, Kelly K M, Kurch L, Link M P, Mauz-Koerholz C, Mccarten K, Punnett A, Stroevesandt D, Flerlage J E

Radiotherapy

Posters

P091

Early analysis of the PRO-Hodgkin study: Clinical investigation of pencil beam scanning proton treatment in Hodgkin Lymphoma patients
Goldkuhl C, Dasu A, Bäck A, Enblad G, Glimelius I, Hall A, Hansson L, Jerlström. U, Johansson A, Kahlmeter-Brandell J, Linderöth J, Palma M, Rylander H, Enmark M, Molin D

P092

Estimating the dosimetric benefit of involved-node radiotherapy in comparison to involved-field radiotherapy - implications from the GHSG HD 17 trial
Oertel M, Hering D, Nacke N, Kittel C, Kröger K, Kriz J, Fuchs M, Baues C, Vordermark D, Engenhardt-Cabillio R, Herfarth K, Lukas P, Schmidberger H, Marnitz S, Borchmann P, Engert A, Haverkamp U, Eich H T

P093

From involved- field to involved-node - Quality analysis of the radiation therapy in HD 17 by the expert panel of the German Hodgkin Study Group

Oertel M, Hering D, Nacke N, Kittel C, Kröger K, Kriz J, Fuchs M, Baues C, Vordermark D, Engenhardt-Cabilllic R, Herfarth K, Lukas P, Schmidberger H, Marnitz S, Borchmann P, Engert A, Haverkamp U, Eich H T

P094

Long-term outcomes of bulky classic Hodgkin Lymphoma managed with a PET-adapted approach demonstrate excellent outcomes in PET-negative cases

Kim J L, Villa D, Tonseth R P, Gerrie A S, Wilson D, Benard F, Venner C, Skinnider B, Farinha P, Slack G W, Scott D W, Connors J M, Sehn L H, Savage K J

P095

Personalised Modelling of Quality-Adjusted Survival Benefit and Cost-Effectiveness of using Proton Beam Therapy in the Treatment of Intermediate-Stage Hodgkin Lymphoma in England

Jones D, Shakir R, Candio P, Ramroth J, Wolstenholme J, Gray A, Cutter D, Ntents G

P096

Polymorphisms in SETD7 may predispose the risk of developing late cardiac side effects after radiotherapy including the mediastinum in Hodgkin's Lymphoma

Linderoth J, Freyhult E, Andreasson E, Johansson A, Andersson A, Glimelius I, Enblad G, Molin D

P097

The status quo of involved-field radiotherapy - Quality analysis of radiotherapy in the GHSG HD 16

Oertel M, Hering D, Kittel C, Nacke N, Kröger K, Kriz J, Fuchs M, Baues C, Vordermark D, Engenhardt-Cabilllic R, Herfarth K, Lukas P, Schmidberger H, Marnitz S, Borchmann P, Haverkamp U, Engert A, Eich H T

Relapsed / Refractory**Talks****Q T098**

Brentuximab Vedotin plus ESHAP (BRESHAP) versus ESHAP in Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma. Interim Results of the BRESELIBET Prospective Clinical Trial
Sureda-Balari A, Terol M J, Domingo-Domènech E, González Rodríguez A P, Hernández Mohedo F, Núñez Céspedes J, De La Cruz Vicente F, Martínez Muñoz C, Amutio Díaz M E, Córdoba R, Rodríguez Izquierdo A, Romero Domínguez S, Briones Mejjide J, Greil R, Moreno Velázquez M, Rubio A, Bastos Oteiro M, Gómez P, Avivi I, Casanova M, Del Campo García R, Noriega V, Sánchez Blanco J J, García Sanz R

Q T099

High efficacy and durability of second-line therapy with pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin in the phase II study for relapsed and refractory Hodgkin Lymphoma
Moskowitz A J, Shah G, Schöder H, Ganesan N, Hancock H, Davey T, Perez L, Sohail S, Santarosa A, Capadona C, Munayirji B, Kumar A, Lahoud O, Battevi C, Hamlin P, Straus D J, Owens C, Caron P, Intlekofer A, Hamilton A, Horwitz S, Falchi L, Johnson W, Palomba L, Noy A, Matasar M, Pongas G, Salles G, Vardhana S, Sanin B W, Yahalom J, Dogan A, Zelenetz A, Moskowitz C H

Q T100

Long term Follow-up of a Phase I Study Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed / Refractory Hodgkin Lymphoma: A trial of the ECOG-ACRIN Research Group (E4412: Arms A-I)
Diefenbach C, Jegede O, Ambinder R, Cohen J, Robertson M, David K, Advani R, Fenske T, Barta S, Palmisiano N, Svoboda J, Morgan D, Karmali R, Kahl B, Ansell S M

P101

Combination of immune checkpoint inhibitors with BeGEV in the treatment of patients with relapsed and refractory classical Hodgkin's Lymphoma

Mangasarova Y, Moiseeva T, Al-Radi L, Margolin O, Gorenkova L, Nesterova E, Bagova M, Fastova E, Abdurashidova R, Sarakaeva Z, Dorokhina E, Kravchenko S, Magomedova A, Zvonkov E

P102

Comparison of Novel Salvage Regimens and Traditional salvage Chemotherapy in Relapsed and Refractory Classic Hodgkin Lymphoma

Shah H, Vardell V, Zacholski E, Fegley A, Fedak K, Sundaram S, Rajeeve S, Goyal G, Hatic H, Torka P, Aqeel S B, Borogovac A, Macdougall K, Kothari S, Kress A, Modi D, Travers E, Chilakamarri N, Brem E, Stephens D M, Hu B, Fitzgerlad L, Wagner C, Ermann D

P103

Comparison of PET-derived parameters in program cell death-1 inhibitor and CD30 antibody drug conjugate-based therapies in patients with advanced stage cHL: A single center experience.

Kamel S, Martiniova L, Aboismail E, Schmidt J, Ahmed S, Nair R, Steiner R E, Wang M L, Soebianto S, Ravizzini G, Pan T, Lee H J

P104

Consolidation Therapy with Brentuximab Vedotin after Autologous Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma in the Czech Republic

Michalka J, Marková J, Gahérová L, Maco M, Procházková V, Kořen J, Sýkorová A, Štěpánková P, Steinerová K, Mohammad L, Ďuraš J, Velacková B, Doležal T, Benešová K, Lukášová M, Janíková A, Král Z, Mócíková H

P105

Decisional role of interim PET in relapsed/refractory classical Hodgkin Lymphoma treated with four begev cycles

Rusconi C, Ricci F, Zilioli V R, Marasco V, Calabretta E, Guidetti A, Muzi C, Mazzon F, Smania M, Sollini M, Meli E, Rodari M, Ravano E, Cairoli R, Corradini P, Santoro A

P106

Dose intensive brentuximab vedotin for platinum resistant recurrent Hodgkin Lymphoma is a feasible treatment option - a single center experience

Erenmalm A, Linderoth J

P107

Effect of Brentuximab Vedotin Addition to Chemotherapy and Prognostic Factors in Patients with Relapsed/Refractory Hodgkin Lymphoma: a Large Multi-Trial Analysis Based on Individual Patient Data

Driessen J, De Wit F, Herrera A F, Zinzani P L, Lacasce A S, Cole P D, Moskowitz C H, Garcia Sanz R, Fuchs M, Müller H, Borchmann P, Santoro A, Schöder H, Zijlstra J M, Hutten B A, Moskowitz A J, Kersten M J

P108

Integrating baseline circulating tumor DNA with interim PET improves outcome prediction in relapsed/refractory classical Hodgkin Lymphoma

Calabretta E, Di Trani M, Sollini M, Ricci F, Corrado F, Cristaldi V, Bonovas S, Marino F, Mazza R, Terzi Di Bergamo L, Brusca G, Piroso M C, Bramanti S, Chiti A, Santoro A, Rossi D, Carlo-Stella C

P109

One-Day Brentuximab-Bendamustine (120mg/m²) every 21 days is a feasible and safe treatment for relapsed/refractory Hodgkin Lymphoma

Moatti H, Laroque M, Renaud L, Ravdan O, Schmidt-Hieber C, Madelaine I, Di Blasi R, Thieblemont C, Brice P

P110

Outcome of high-dose chemotherapy (HDCT) and autologous stem cell transplant (ASCT) as first salvage treatment for relapsed or refractory classical Hodgkin Lymphoma (cHL) in the era of PET-adapted strategy among Italian centers

Viviani S, Vanazzi A, Frassoni S, Rusconi C, Rossi A, Romano A, Patti C, Schiavotto C, Sorasio R, Marasco V, Lissandrini L, Rapezzi D, Gottardi D, Cocito F, Mulè A, Gini G, Zanotti R, Rambaldi A, Bagnardi V, Tarella C

P111

Phase I Trial of Brentuximab Vedotin plus Cyclosporine in Relapsed/Refractory Hodgkin Lymphoma

Kambhampati S, Mei M, Chen L, Puvurel S, Chen R, Popplewell L, Nikolaenko L, Peters L, Armenian S, Kwak L, Rosen S T, Forman S, Herrera A F

P112

Phase II Trial of Brentuximab Vedotin plus ibrutinib in Relapsed/Refractory Hodgkin Lymphoma

Mei M, Palmer J, Maddocks K, Martin P, Tsai N, Smith E, Popplewell L, Armenian S, Shouse G, Chen R, Kwak L, Rosen S T, Forman S, Bond D, Herrera A F

P113

Promising results with anti-PD-1 therapy in primary refractory Hodgkin Lymphoma: a single-centre report

Zerbi C, Lazic T, Sciarra R, Cristinelli C, Mazzacane A, Carpi F, Ferretti V V, Gambini G, Bonfichi M, Arcaini L, Gotti M

P114

Very late relapses in patients with Hodgkin Lymphoma occurring >e;5 years after initial treatment with chemotherapy ± radiotherapy:

Treatment strategies and prognostic factors for the outcome

Vassilakopoulos T P, Liaskas A, Rizzuto G, Symeonidis A, Palma M, Angelopoulou M K, Giatra C, Kondopidou F, Dimou M, Musseti A, Xagoraris I, Siakantaris M, Verigou E, Panitsas F, Asimakopoulos J, Arapaki M, Chatzidimitriou C, Belia M, Sachanas S, Korkolopoulou P, Cabras A, Variamis E, Panayiotidis P, Bakiri M, Karmiris T, Rassidakis G Z, Corradini P, Pangalis G, Viviani S

SPEAKERS AND CHAIRS

Advani, Ranjana: *radvani@stanford.edu*
Aleman, Berthe: *b.aleman@nki.nl*
André, Marc: *marc.andre@uclouvain.be*
Ansell, Stephen: *ansell.stephen@mayo.edu*
Armand, Philippe: *Philippe_Armand@dfci.harvard.edu*
Baiocchi, Otavio: *obaocchi@gmail.com*
Barrington, Sally: *sally.barrington@kcl.ac.uk*
Baues, Christian: *christian.baues@uk-koeln.de*
Behringer, Karolin: *karolin.behringer@uk-koeln.de*
Binkley, Michael S.: *msb996@stanford.edu*
Björkholm, Magnus: *magnus.bjorkholm@sl.se*
Borchmann, Peter: *Peter.Borchmann@uni-koeln.de*
Borchmann, Sven: *sven.borchmann@uk-koeln.de*
Bröckelmann, Paul: *paul.broeckelmann@uk-koeln.de*
Buvat, Irene: *irene.buvat@u-psud.fr*
Casasnovas, Olivier: *olivier.casasnovas@chu-dijon.fr*
Cramer, Paula: *paula.cramer@uk-koeln.de*
Collins, Graham: *graham.collins@ouh.nhs.uk*
Cordoba Mascuñano, Raul: *raul.cordoba@fjd.es*
Cutter, David: *david.cutter@ndph.ox.ac.uk*
Diehl, Volker: *v.diehl@uni-koeln.de*
Dierickx, Daan: *daan.dierickx@uzteuven.be*
Dreyling, Martin: *Martin.Dreyling@med.uni-muenchen.de*
Eich, Hans: *hans.eich@ukmuenster.de*
Eichenauer, Dennis: *dennis.eichenauer@uk-koeln.de*
Evens, Andrew: *ae378@cinj.rutgers.edu*
Flerlage, Jamie: *jamie.flerlage@stjude.org*
Fossa, Alexander: *aff@ous-hf.no*
Friedberg, Jonathan: *jonathan_friedberg@urmc.rochester.edu*
Glimelius, Ingrid: *ingrid.glimelius@igp.uu.se*
Hartmann, Sylvia: *s.hartmann@em.uni-frankfurt.de*
Heger, Michel: *jan-michel.heger@uk-koeln.de*
Herrera, Alex: *aherrera@coh.org*
Hertzberg, Mark: *mhertzberg10@gmail.com*
Hoppe, Richard: *Richard.Hoppe@stanford.edu*
Howe, Tracy: *tracy.howe4@nhs.net*
Hutchings, Martin: *martin.hutchings@gmail.com*
Illidge, Tim: *Tim.Illidge@ics.manchester.ac.uk*

Imber, Brandon: *imberb@mskcc.org*
Jacob, Anne Sophie: *anne.jacob@uk-koeln.de*
Jennings, Louise: *louisejennings24@hotmail.com*
Kersten, Marie José: *m.j.kersten@amsterdamumc.nl*
Klapper, Wolfram: *wklapper@path.uni-kiel.de*
Kobe, Carsten: *carsten.kobe@uk-koeln.de*
Körholz, Dieter: *dieter.koerholz@paediat.med.uni-giessen.de*
Küppers, Ralf: *ralf.kueppers@uk-essen.de*
Linton, Kim: *Kim.M.Linton@manchester.ac.uk*
Mauz-Körholz, Christine: *christine.mauz-koerholz@paediat.med.uni-giessen.de*
Mellinghoff, Sybille: *sibylle.mellinghoff@uk-koeln.de*
Meriranta, Leo: *leo.meriranta@helsinki.fi*
Moskowitz, Alison: *moskowitz@mskcc.org*
Moskowitz, Craig: *CHM78@miami.edu*
Oeffinger, Kevin: *kevin.oeffinger@duke.edu*
Parsons, Susan: *sparsons@tuftsmedicalcenter.org*
Pegtel, Michiel: *d.pegstel@vumc.nl*
Pinczés, László Imre: *pinczes.laszlo.imre@med.unideb.hu*
Pirosa, Cristina: *Maria.Pirosa@eoc.ch*
Quintarelli, Conchetta: *conchetta.quintarelli@opbg.net*
Radford, John: *John.Radford@manchester.ac.uk*
Richardson, Jack: *jrojr92@googlemail.com*
Rodig, Scott: *srodig@bwh.harvard.edu*
Rosenwald, Andreas: *rosenwald@uni-wuerzburg.de*
Rossi, Davide: *Davide.Rossi@eoc.ch*
Savoldo, Barbara: *bsavoldo@med.unc.edu*
Schaapveld, Michael: *m.schaapveld@nki.nl*
Shipp, Margaret: *Margaret_shipp@dfci.harvard.edu*
Specht, Lena: *specht@rh.dk*
Steidl, Christian: *CSteidl@bccancer.bc.ca*
Sureda, Anna: *asureda@iconcologia.net*
Tucci, Alessandra: *alessandra.tucci@asst-spedaliciivli.it*
van Leeuwen, Flora: *f.v.leeuwen@nki.nl*
von Tresckow, Bastian: *Bastian.vonTresckow@uk-essen.de*
Wells, Sarah: *s.wells7@nhs.net*
Yahalom, Joachim: *yahalomj@mskcc.org*
Zijlstra, Jose: *j.zijlstra@amsterdamumc.nl*
Zinzani, Pierluigi: *pierluigi.zinzani@unibo.it*



POSTER AWARD

Lilian Beeck

Julia Driessen

David Jones

Laman Mammadova

Andrea Visentin

KARL MUSSHOF PRIZE

Best Clinical Abstract

The Karl Musshoff Foundation was established by Professor Karl Musshoff in 1997. The Karl Musshoff Prize is granted during ISHL in Cologne for outstanding results and contribution to the field of Hodgkin Lymphoma.

This year's prize in the category "Best Clinical Abstract" will be awarded to:

ALISON MOSKOWITZ

KARL MUSSHOF PRIZE


Best Preclinical Abstract

The Karl Musshoff Foundation was established by Professor Karl Musshoff in 1997. The Karl Musshoff Prize is granted during ISHL in Cologne for outstanding results and contribution to the field of Hodgkin Lymphoma.

This year's prize in the category "Best Preclinical Abstract" will be awarded to:

JULIA PACZKOWSKA

GÜRZENICH CONGRESS CENTER



First Floor "Großer Saal"

Sat.	22.10.2022	Seminars, Workshops, Scientific Symposia, Scientific Program, Opening Ceremony
Sun.	23.10.2022	Scientific Program, Scientific Symposia
Mon.	24.10.2022	Scientific Program, Scientific Symposia

First Floor "Isabellensaal"

Sat. (noon) - Mon.	22.-24.10.2022	Exhibition Hall, Coffee Bar
--------------------	----------------	-----------------------------

Ground Floor "Kleiner Saal"

Sat.	22.10.2022	Seminars, Workshops
------	------------	---------------------

Ground Floor "Marsiliussaal"

Sat.	22.10.2022	Seminars, Workshops
------	------------	---------------------

Foyer Ground Floor

Sat. - Mon.	22.-24.10.2022	Registration, Internet, Speakers Ready Room
Sat.	22.10.2022	Poster Session with Welcome Reception

Basement "Ratsstube", "Weinkeller"

Sat.	22.10.2022	Seminars, Workshops
------	------------	---------------------

WC : First Floor, Basement

Further information will be available at
www.hodgkinsymposium.org

ISHL 13



ISHL12

FOR YOUR MOBILE

Please bookmark URL or use QR-Code
app.ishl.eu